Medical Aesthetics Market to Gain Revenue Due to Shift in the Preference from Surgical to Non-Surgical Procedures

06/set/2017 07:33:17 Pramod Kumar Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

As for the findings of research, injectables held the largest share in the global market in 2016, primarily due to high sales of botulinum toxin. Topicals, the second largest medical aesthetics product segment, witnessed the highest growth during 2013 - 2016. The highest growth of topicals is attributed to their ability to treat multiple skin conditions without any use of uncomfortable procedures. Beauty clinics and centers was the largest end user of the global medical aesthetics market in 2016, followed by spas and salons.

Request for a sample of this research report:

Geographically, North America has been the largest market for medical aesthetics, with the US being the largest contributor to the regional market. North America is considered as the platform for innovation in aesthetics procedures, since most established and upcoming market players are either headquartered or have a significant geographical presence in the region. The emerging economies of Asia-Pacific, especially China and India, are expected to grow tremendously in the future, which will make Asia-Pacific the second-largest market in the coming years. Asia-Pacific is expected to outpace Europe in terms of medical aesthetics market size by 2020.

Make an inquiry before buying the report:

The medical aesthetics market has recently witnessed a number of mergers and acquisitions and strategic alliances. In December 2016, Allergan Plc. acquired LifeCell, a medicine company of Acelity LP Inc., for a cash consideration of $ 2.9 billion. The acquisition is expected to combine LifeCell's business of regenerative medicine with Allergan's medical aesthetics business. Allergan aims to strengthen its presence in regenerative medicine business with this acquisition. In April 2016, the company also acquired Topokine Therapeutics, a private company developing topical drugs for fat reduction, for a total consideration of $ 85.0 million. Topokine Therapeutics' XAF5 is in late-stage development for the treatment of steatoblepharon.

Some of the other key players in the market include Allergan Plc, Valeant Pharmaceuticals International, Inc., ZELTIQ Aesthetics, Inc. Johnson & Johnson, Cutera Inc., Alma Lasers Ltd., Merz GmbH & Co. KGaA, Galderma SA, Syneron Medical Ltd., Cynosure, Inc., Photomedex, Inc. and Lumenis Ltd.

Mr. Kundan Kumar

Manager - Client Partner

347, 5th Ave. # 1402

New York City, NY - 10016

Toll-free: +18887787886 (USA / Canada)



Connect with us: LinkedIn | Twitter | Google+ | Facebook

blog comments powered by Disqus è un servizio offerto da Factotum Srl